Trial Profile
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2022
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 14 Dec 2021 Results reporting optimization of autologous hematopoietic progenitor stem cell apheresis collection from Plerixafor mobilized patients enrolled on two clinical trials (NCT03226691 and NCT04443907) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 06 Nov 2019 Results assessing efficacy and safety of plerixafor mobilization in patients with sickle cell disease, released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 28 Feb 2019 Status changed from recruiting to completed.